GPX4 Levels in Ankylosing Spondylitis and Axial Psoriatic Arthritis
Official title: Identification of Glutathione Peroxidase 4 in Detecting Ferroptosis in Ankylosing Spondylitis and Axial Psoriatic Arthritis Patients .
Run by Assiut University · NCT06554392 · Data updated 2026-11-12
This study tests whether the enzyme GPX4 is different in people with ankylosing spondylitis or axial psoriatic arthritis compared with typical levels in blood.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 85 (estimated) |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Asyut) |
| Status | Recruiting |
| Started | September 1, 2024 |
| Main results expected | September 1, 2027 |
| Study ends | July 1, 2028 |
| Registry record updated | November 5, 2026 |
| Trial ID | NCT06554392 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults diagnosed with ankylosing spondylitis or axial psoriatic arthritis who are willing to provide a blood sample.
✕Probably not a fit
Patients with other autoimmune diseases or major organ dysfunction, or those taking certain drugs, may not benefit from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study analyzes blood samples to measure glutathione peroxidase 4 (GPX4) levels in patients with ankylosing spondylitis or axial psoriatic arthritis. It aims to explore how GPX4 relates to disease activity and severity. The background considers ferroptosis, a form of iron-dependent cell death linked to lipid peroxidation and oxidative stress, and how this process may interact with immune function and autoimmunity in spondyloarthropathies. Participants are adults diagnosed by ASAS or CASPAR criteria, with exclusions for other autoimmune diseases and major organ dysfunction. The lead sponsor is Assiut University, with the study based at the Faculty of Medicine, Assiut University in Asyut.
Why it matters
Potential benefit: If GPX4 is linked to disease activity, this could guide future biomarkers or therapies for spondyloarthropathies.
How similar studies have gone: Previous research has begun to link ferroptosis pathways with autoimmune diseases, but this specific GPX4-blood level association in these conditions is exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed as ankylosing spondylitis according to ASAS criteria . \[13\] * Patients diagnosed as psoriatic arthritis according to CASPAR criteria. \[14\] * Age (\>18). Exclusion Criteria: * Patient with other autoimmune Rheumatic diseases. * patients with any of the following conditions: I) severe liver and kidney dysfunction; II) hematopoietic diseases; III) infectious diseases; IV) tumors; or V) other wasting diseases. \[15\] * patients received certain drugs (for example, sulfasalazine, artemisinin, statins), and experimental reagents (such as erastin) .\[16\]
Where it's running
-
Faculty of Medicine- Assiut University
Asyut, Egypt Recruiting
Study contacts
- Principal investigator: Marwa Mahmoud Abdelaziz, M.D — Rheumatology,Rehabilition Department ,Assiut university
- Study coordinator: Marwa Mahmoud Abdelaziz, M.D
- Email: marwa.ali3@med.aun.edu.eg
- Phone: +201069052233
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.